Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia. The ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8711 ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8540 ...

ENCell announced on the 14th that it has signed a memorandum of understanding (MOU) with Japan's Cellresource (CRC) for collaboration in the cell and gene therapy (CGT) sector. ENCell explained ...

Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside factors of TAK stock.